# Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

> **NCT03697564** · PHASE2 · COMPLETED · sponsor: **Hitendra Patel** · enrollment: 2 (actual)

## Conditions studied

- Pancreatic Cancer Stage IV

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]
- **DRUG:** Cabiralizumab

## Key facts

- **NCT ID:** NCT03697564
- **Lead sponsor:** Hitendra Patel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-31
- **Primary completion:** 2023-04-12
- **Final completion:** 2023-07-13
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2025-08-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03697564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03697564, "Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03697564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*